1. Drugmaker Intarcia Therapeutics cuts 20% of workforce, terminates 2 late-stage trials: 8 things to know
Intarcia Therapeutics, a biopharmaceutical company based in Boston, recently laid off 60 employees and terminated two late-stage trials of its lead diabetes treatment.
2. Sanofi Genzyme to lay off 130 employees at Boston plant
Sanofi Genzyme will lay off 130 workers this week at its manufacturing plant in Boston in an effort to reduce costs and simplify operations.
3. Teva to close Puerto Rico plant, cut 200 jobs as part of restructuring plan
Teva Pharmaceuticals will close its manufacturing plant in Manati, Puerto Rico this month, which will eliminate approximately 200 jobs.
4. Glaxo replaces 40% of top staff, including CEO, in 9 months to spur growth
GlaxoSmithKline replaced roughly 50 of the 125 top managers, including the company’s former CEO, since Emma Walmsley began in her role as head of the company last April. She said the restructuring represents an effort to increase diversity within the team and bring new ideas and skills to Glaxo’s workforce.
5. Pfizer to cut 300 jobs, end drug research for Parkinson’s and Alzheimer’s
Pfizer will end research into treatments for Alzheimer’s and Parkinson’s disease, resulting in the elimination of 300 positions at the company’s Massachusetts facilities in Andover and Cambridge, and its Connecticut facility in Groton.
6. Allergan to cut more than 1k jobs: 3 things to know
Allergan will eliminate more than 1,000 positions in anticipation of generic competition surrounding its popular dry-eye drug Restasis.
7. Teva Pharmaceuticals to cut more than 25% of workforce, consolidate US sites
Teva Pharmaceutical Industries, which is grappling with $35 billion of debt, announced plans Dec. 14 to cut 14,000 jobs worldwide and consolidate six of its seven U.S. sites into one location.
More articles on supply chain:
Celgene Executive Chairman Bob Hugin abruptly steps down: 5 things to know
As flu rages throughout Florida, Tamiflu supplies run low
Pfizer’s opioid-filled syringes hit another manufacturing snag: 6 things to know
